Search Results - "MUNIER, M. L. C"

Mucosal‐associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy‐related colitis in a pathology distinct from ulcerative colitis by Sasson, S. C., Zaunders, J. J., Nahar, K., Munier, C. M. L., Fairfax, B. P., Olsson‐Brown, A., Jolly, C., Read, S. A., Ahlenstiel, G., Palendira, U., Scolyer, R. A., Carlino, M. S., Payne, M. J., Cheung, V. T. F., Gupta, T., Klenerman, P., Long, G. V., Brain, O., Menzies, A. M., Kelleher, A. D.

“…Mucosal‐associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy‐related…”
Get full text

PB2087: EFFICACY OF A 3RD COVID VACCINE, INCLUDING DURING A BTKI PAUSE, IN INDIVIDUALS WITH WALDENSTRÖM MACROGLOBULINEMIA AND FOLLICULAR LYMPHOMA by Rankin, K., Beaton, B., Sasson, S., Raedemaecker, J., Wong, A., Hastak, P., Phetsouphanh, C., Warden, A., Patel, M., Klemm, V., Munier, C. M. L., Carey Hoppe, A., Tea, F., Pillay, A., Ospina, A., Aggarwal, A., Lavee, O., Caterson, I. D., Turville, S., Kelleher, A. D., Brilot, F., Trotman, J.

Get full text

Tissue-based activation of mucosal-associated invariant T (MAIT) cells in combination ipilimumab and nivolumab checkpoint inhibitor (CI) colitis by Sasson, S.C., Cheung, V.T.F., Gupta, T., Zaunders, J.J., Nahar, K., Munier, C M-L, Olsson-Brown, A., Ahlenstiel, G., Palendira, U., Scolyer, R.A., Carlino, M.S., Long, G.V., Menzies, A.M., Kelleher, A., Payne, M., Fairfax, B., Middleton, M.R., Klenerman, P., Brain, O.

Get full text

1303P - Tissue-based activation of mucosal-associated invariant T (MAIT) cells in combination ipilimumab and nivolumab checkpoint inhibitor (CI) colitis by Sasson, S.C., Cheung, V.T.F., Gupta, T., Zaunders, J.J., Nahar, K., Munier, C M-L, Olsson-Brown, A., Ahlenstiel, G., Palendira, U., Scolyer, R.A., Carlino, M.S., Long, G.V., Menzies, A.M., Kelleher, A., Payne, M., Fairfax, B., Middleton, M.R., Klenerman, P., Brain, O.

“…Up to 44% of patients receiving combination ipilimumab and nivolumab develop checkpoint-inhibitor-(CI) colitis, however its molecular pathogenesis is poorly…”
Get full text

1303PTissue-based activation of mucosal-associated invariant T (MAIT) cells in combination ipilimumab and nivolumab checkpoint inhibitor (CI) colitis by Sasson, S C, Cheung, V T F, Gupta, T, Zaunders, J J, Nahar, K, Munier, C M-L, Olsson-Brown, A, Ahlenstiel, G, Palendira, U, Scolyer, R A, Carlino, M S, Long, G V, Menzies, A M, Kelleher, A, Payne, M, Fairfax, B, Middleton, M R, Klenerman, P, Brain, O

“…Abstract Background Up to 44% of patients receiving combination ipilimumab and nivolumab develop checkpoint-inhibitor-(CI) colitis, however its molecular…”
Get full text

PB2087: EFFICACY OF A 3RD COVID VACCINE, INCLUDING DURING A BTKI PAUSE, IN INDIVIDUALS WITH WALDENSTRÖM MACROGLOBULINEMIA AND FOLLICULAR LYMPHOMA by Rankin, K., Beaton, B., Sasson, S., Raedemaecker, J., Wong, A., Hastak, P., Phetsouphanh, C., Warden, A., Patel, M., Klemm, V., Munier, C. M. L., Carey Hoppe, A., Tea, F., Pillay, A., Ospina, A., Aggarwal, A., Lavee, O., Caterson, I. D., Turville, S., Kelleher, A. D., Brilot, F., Trotman, J.

Get full text

The transforming growth factor-β superfamily cytokine macrophage inhibitory cytokine-1 is present in high concentrations in the serum of pregnant women by MOORE, A. G, BROWN, D. A, FAIRLIE, W. D, BAUSKIN, A. R, BROWN, P. K, MUNIER, M. L. C, RUSSELL, P. K, SALAMONSEN, L. A, WALLACE, E. M, BREIT, S. N

Get full text

The Transforming Growth Factor-β Superfamily Cytokine Macrophage Inhibitory Cytokine-1 Is Present in High Concentrations in the Serum of Pregnant Women1 by Moore, A. G., Brown, D. A., Fairlie, W. D., Bauskin, A. R., Brown, P. K., Munier, M. L. C., Russell, P. K., Salamonsen, L. A., Wallace, E. M., Breit, S. N.

“…Macrophage inhibitory cytokine-1 (MIC-1) is a recently described divergent member of the transforming growth factor-β superfamily. MIC-1 transcription…”
Get full text